Shares of Quest Diagnostics Inc (NYSE:DGX) have earned an average recommendation of “Hold” from the twenty-three brokerages that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, fifteen have given a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $104.83.

A number of research analysts recently issued reports on the stock. Zacks Investment Research downgraded shares of Quest Diagnostics from a “hold” rating to a “sell” rating in a research report on Friday, October 27th. Mizuho set a $103.00 target price on shares of Quest Diagnostics and gave the company a “buy” rating in a research report on Thursday, October 19th. Canaccord Genuity boosted their target price on shares of Quest Diagnostics from $100.00 to $105.00 and gave the company a “buy” rating in a research report on Thursday, October 26th. Evercore ISI assumed coverage on shares of Quest Diagnostics in a research report on Thursday. They set an “in-line” rating and a $103.00 target price on the stock. Finally, SunTrust Banks set a $105.00 target price on shares of Quest Diagnostics and gave the company a “hold” rating in a research report on Sunday, October 15th.

In other Quest Diagnostics news, EVP J. E. Davis sold 63,880 shares of the company’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $98.68, for a total transaction of $6,303,678.40. Following the transaction, the executive vice president now owns 101,423 shares in the company, valued at $10,008,421.64. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 1.75% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Thrivent Financial For Lutherans raised its holdings in Quest Diagnostics by 2.0% during the second quarter. Thrivent Financial For Lutherans now owns 5,200 shares of the medical research company’s stock worth $578,000 after buying an additional 100 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its stake in shares of Quest Diagnostics by 3.5% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,894 shares of the medical research company’s stock worth $434,000 after acquiring an additional 131 shares in the last quarter. D.A. Davidson & CO. grew its stake in shares of Quest Diagnostics by 1.2% in the 2nd quarter. D.A. Davidson & CO. now owns 12,788 shares of the medical research company’s stock worth $1,421,000 after acquiring an additional 147 shares in the last quarter. Neuberger Berman Group LLC grew its stake in shares of Quest Diagnostics by 0.5% in the 2nd quarter. Neuberger Berman Group LLC now owns 37,282 shares of the medical research company’s stock worth $4,144,000 after acquiring an additional 189 shares in the last quarter. Finally, Pacer Advisors Inc. grew its stake in shares of Quest Diagnostics by 8.1% in the 2nd quarter. Pacer Advisors Inc. now owns 2,710 shares of the medical research company’s stock worth $301,000 after acquiring an additional 203 shares in the last quarter. Hedge funds and other institutional investors own 88.84% of the company’s stock.

Shares of Quest Diagnostics (DGX) traded up $0.15 during midday trading on Friday, hitting $99.22. 276,433 shares of the stock were exchanged, compared to its average volume of 1,200,000. The firm has a market cap of $13,520.00, a P/E ratio of 20.67, a P/E/G ratio of 2.03 and a beta of 0.60. Quest Diagnostics has a 1 year low of $90.10 and a 1 year high of $112.96. The company has a quick ratio of 1.37, a current ratio of 1.47 and a debt-to-equity ratio of 0.78.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings results on Thursday, October 19th. The medical research company reported $1.39 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.35 by $0.04. The firm had revenue of $1.93 billion for the quarter, compared to the consensus estimate of $1.92 billion. Quest Diagnostics had a net margin of 8.82% and a return on equity of 15.53%. The company’s revenue for the quarter was up 2.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.37 EPS. sell-side analysts expect that Quest Diagnostics will post 5.65 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 24th. Shareholders of record on Tuesday, January 9th will be issued a dividend of $0.45 per share. The ex-dividend date of this dividend is Monday, January 8th. This represents a $1.80 annualized dividend and a yield of 1.81%. Quest Diagnostics’s payout ratio is 37.50%.

ILLEGAL ACTIVITY NOTICE: “Quest Diagnostics Inc (DGX) Given Consensus Recommendation of “Hold” by Analysts” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/01/05/quest-diagnostics-inc-dgx-given-consensus-recommendation-of-hold-by-analysts.html.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Analyst Recommendations for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.